TRPC3 and COVID-19: As the USA has initiated a clinical trial of ibudilast to treat acute respiratory distress syndrome (ARDS) in COVID-19 patients [58], further studies focusing on TRPC3-Nox2 protein–protein interactions may establish a new strategy for the prevention or treatment against human COVID-19 severity and vaccine side effects.